The Role of Atypical Cannabinoid Ligands O-1602 and O-1918 on Skeletal Muscle Homeostasis with a Focus on Obesity.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Aug 2020
Historique:
received: 18 06 2020
revised: 28 07 2020
accepted: 13 08 2020
entrez: 23 8 2020
pubmed: 23 8 2020
medline: 17 2 2021
Statut: epublish

Résumé

O-1602 and O-1918 are atypical cannabinoid ligands for GPR55 and GPR18, which may be novel pharmaceuticals for the treatment of obesity by targeting energy homeostasis regulation in skeletal muscle. This study aimed to determine the effect of O-1602 or O-1918 on markers of oxidative capacity and fatty acid metabolism in the skeletal muscle. Diet-induced obese (DIO) male Sprague Dawley rats were administered a daily intraperitoneal injection of O-1602, O-1918 or vehicle for 6 weeks. C

Identifiants

pubmed: 32824681
pii: ijms21165922
doi: 10.3390/ijms21165922
pmc: PMC7460607
pii:
doi:

Substances chimiques

1,3-dimethoxy-5-methyl-2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)benzene 0
APPL2 protein, human 0
Adaptor Proteins, Signal Transducing 0
Anisoles 0
Cyclohexanes 0
Fatty Acids 0
GPR18 protein, human 0
NFATC Transcription Factors 0
NFATC1 protein, human 0
PDK4 protein, human 0
PPAR gamma 0
Pyruvate Dehydrogenase Acetyl-Transferring Kinase 0
Receptors, G-Protein-Coupled 0
Cannabidiol 19GBJ60SN5
O-1602 compound 317321-41-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Allen Foundation
ID : Project ID 2011.385

Références

J Musculoskelet Neuronal Interact. 2006 Jan-Mar;6(1):73-86
pubmed: 16675891
Diabetologia. 2009 Oct;52(10):2015-26
pubmed: 19547950
Diabetes. 1997 Jun;46(6):983-8
pubmed: 9166669
Diabetes. 2012 Feb;61(2):281-91
pubmed: 22179809
Br J Pharmacol. 2014 Aug;171(16):3908-17
pubmed: 24762058
Histochem Cell Biol. 2015 Jul;144(1):49-58
pubmed: 25869640
Ann N Y Acad Sci. 1977;301:3-29
pubmed: 73362
BMC Neurosci. 2010 Mar 26;11:44
pubmed: 20346144
Int J Mol Sci. 2019 Sep 07;20(18):
pubmed: 31500240
Genes Dev. 2003 Sep 15;17(18):2205-32
pubmed: 12975316
Mol Cell Endocrinol. 2013 Jan 5;365(1):108-18
pubmed: 23069642
Cell Metab. 2005 Jun;1(6):361-70
pubmed: 16054085
Br J Pharmacol. 2016 Apr;173(7):1128-42
pubmed: 25537025
FASEB J. 2019 Jan;33(1):1299-1312
pubmed: 30148676
Front Physiol. 2016 Oct 25;7:476
pubmed: 27826249
Ann Med. 2005;37(4):270-5
pubmed: 16019725
Mol Cell Biochem. 2016 May;416(1-2):131-9
pubmed: 27067870
J Endocrinol. 2011 Nov;211(2):177-85
pubmed: 21885477
BMC Biotechnol. 2003 Oct 13;3:18
pubmed: 14552656
Mol Pharmacol. 2003 Mar;63(3):699-705
pubmed: 12606780
Endocr Connect. 2019 Mar 1;8(3):203-216
pubmed: 30707678
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Inflamm Bowel Dis. 2011 Aug;17(8):1651-64
pubmed: 21744421
Mol Cell Endocrinol. 2007 Mar 15;267(1-2):63-9
pubmed: 17270342
Endocr Rev. 2006 Feb;27(1):73-100
pubmed: 16306385
Mol Endocrinol. 2011 Nov;25(11):1835-48
pubmed: 21964594
Eur J Pharmacol. 2018 Feb 5;820:256-264
pubmed: 29274332
Obes Res Clin Pract. 2007 Jan;1(1):1-78
pubmed: 24351431
J Clin Invest. 1990 Nov;86(5):1423-7
pubmed: 2243122
Biochem J. 2011 Jan 1;433(1):175-85
pubmed: 20955176
J Biol Chem. 2009 Nov 13;284(46):31608-15
pubmed: 19661063
Eur J Pharmacol. 2019 Jul 5;854:372-379
pubmed: 31054273
Mol Cell Biol. 2005 Dec;25(24):10684-94
pubmed: 16314495
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Clin Endocrinol Metab. 2016 Sep;101(9):3469-78
pubmed: 27294325
Obes Res. 1995 Sep;3(5):459-64
pubmed: 8521165
Drug Discov Today. 2014 Aug;19(8):1145-51
pubmed: 24370891
Diabetes Obes Metab. 2010 Aug;12(8):722-30
pubmed: 20590750
Biochem Biophys Res Commun. 2007 Dec 7;364(1):105-10
pubmed: 17935697
Cell Physiol Biochem. 2011;28(5):949-58
pubmed: 22178946
Am J Physiol Endocrinol Metab. 2018 Jun 1;314(6):E564-E571
pubmed: 29406784
Diabetes Obes Metab. 2012 Mar;14(3):234-43
pubmed: 21981246
J Cardiovasc Pharmacol. 2017 Jan;69(1):23-33
pubmed: 27676325

Auteurs

Anna C Simcocks (AC)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.

Lannie O'Keefe (L)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
First Year College, Victoria University, Melbourne, VIC 8001, Australia.

Kayte A Jenkin (KA)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
School of Science, Western Sydney University, Campbelltown, NSW 2560, Australia.

Lauren M Cornall (LM)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.

Esther Grinfeld (E)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.

Michael L Mathai (ML)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
The Florey Institute of Neuroscience and Mental Health, Melbourne VIC 3052, Australia.

Deanne H Hryciw (DH)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
School of Environment and Sciences, Griffith University, Nathan, QLD 4111, Australia.
Environmental Futures Research Institute, Griffith University, Nathan, QLD 4111, Australia.

Andrew J McAinch (AJ)

Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
Australian Institute for Musculoskeletal Science (AIMSS), College of Health and Biomedicine, Victoria University, Melbourne, VIC 8001, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH